| Original language | English (US) |
|---|---|
| Pages (from-to) | 92-96 |
| Number of pages | 5 |
| Journal | JAAD Case Reports |
| Volume | 15 |
| DOIs | |
| State | Published - Sep 2021 |
Keywords
- CTCL classifications
- Sézary syndrome
- T cell
- clinical cases
- leukemic progression
- lymphoma
- medical dermatology
- mycosis fungoides
ASJC Scopus subject areas
- Dermatology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Acute progression of the leukemic phase in mycosis fungoides and Sézary syndrome. / Maredia, Hasina; Cozzio, Antonio; Dummer, Reinhard et al.
In: JAAD Case Reports, Vol. 15, 09.2021, p. 92-96.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Acute progression of the leukemic phase in mycosis fungoides and Sézary syndrome
AU - Maredia, Hasina
AU - Cozzio, Antonio
AU - Dummer, Reinhard
AU - Ramelyte, Egle
AU - Kim, Ellen J.
AU - Rozati, Sima
N1 - Funding Information: Dr Dummer reports intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp and Dhome, Bristol-Myers Squibb, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, and Alligator outside the submitted work. Dr Ramelyte reports intermittent, project-focused consulting and/or advisory relationships with Amgen, Novartis, Sanofi, Pierre Fabre, and Sun Pharma outside the submitted work. Dr Kim reports grants and personal fees from Actelion and Galderma ; personal fees from Helsinn and Almirall; and grants from MedImmune , Kyowa Kirin , and Soligenix outside the submitted work. Drs Maredia, Cozzio, and Rozati have no conflicts of interest to declare. Funding Information: Dr Dummer reports intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp and Dhome, Bristol-Myers Squibb, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, and Alligator outside the submitted work. Dr Ramelyte reports intermittent, project-focused consulting and/or advisory relationships with Amgen, Novartis, Sanofi, Pierre Fabre, and Sun Pharma outside the submitted work. Dr Kim reports grants and personal fees from Actelion and Galderma; personal fees from Helsinn and Almirall; and grants from MedImmune, Kyowa Kirin, and Soligenix outside the submitted work. Drs Maredia, Cozzio, and Rozati have no conflicts of interest to declare. Funding sources: None.
PY - 2021/9
Y1 - 2021/9
KW - CTCL classifications
KW - Sézary syndrome
KW - T cell
KW - clinical cases
KW - leukemic progression
KW - lymphoma
KW - medical dermatology
KW - mycosis fungoides
UR - http://www.scopus.com/inward/record.url?scp=85112753016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112753016&partnerID=8YFLogxK
U2 - 10.1016/j.jdcr.2021.07.007
DO - 10.1016/j.jdcr.2021.07.007
M3 - Article
C2 - 34458536
AN - SCOPUS:85112753016
SN - 2352-5126
VL - 15
SP - 92
EP - 96
JO - JAAD Case Reports
JF - JAAD Case Reports
ER -